Ongoing trials are evaluating additional PRMT inhibitors, including GSK3368715 (targeting PRMT1) and CMP5 (targeting PRMT5), in patients with advanced malignancies, including breast cancer [[127], [128], [129]]. Here, PRMT5 is linked to breast carcinoma.